U.S. Food and Drug Administration. Daratumumab (DARZALEX). Available from https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm530249.htm. Accessed 05 February 2020.U.S. Food and Drug Administration.. Available from https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm530249.htm. Accessed 05 February 2020.Search in Google Scholar
Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol 2018;9:2722.MorandiFHorensteinALCostaFGiulianiNPistoiaVMalavasiF.CD38: a target for immunotherapeutic approaches in multiple myeloma.2018;9:2722.10.3389/fimmu.2018.02722627987930546360Search in Google Scholar
De Weers M, Tai YT, Van Der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840–8.De WeersMTaiYTVan Der VeerMS,Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.2011;186:1840–8.10.4049/jimmunol.100303221187443Search in Google Scholar
AABB. Mitigating the anti-CD38 interference with serological testing. AABB Assoc Bull #16-02. Bethesda, MD: AABB, 2016.AABB..Bethesda, MD:AABB,2016.Search in Google Scholar
Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015;55:1545–54.ChapuyCINicholsonRTAguadMD,Resolving the daratumumab interference with blood compatibility testing.2015;55:1545–54.10.1111/trf.1306925764134Search in Google Scholar
Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964–72.ChapuyCIAguadMDNicholsonRT,International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.2016;56:2964–72.10.1111/trf.1378927600566Search in Google Scholar
Branch DR, Muensch HA, Hian AL, Petz LD. Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity. Br J Haematol 1983;54:573–8.BranchDRMuenschHAHianALPetzLD.Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity.1983;54:573–8.10.1111/j.1365-2141.1983.tb02136.x6871108Search in Google Scholar
Carrel H, Sutor L, Leparc G, Doty M, Crews W. The long term storage effect of 0.2 M dithiothreitol on red cell antigen integrity in reagent red blood cells. Paper presented at the 2017 AABB Annual Meeting 2017.AABB.CarrelHSutorLLeparcGDotyMCrewsW..Paper presented at the 2017 AABB Annual Meeting 2017.AABB.Search in Google Scholar
Lorenzen H, Lone Akhtar N, Nielsen M, Svendsen L, Andersen P. Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing. Vox Sang 2018;113:686–93.LorenzenHLone AkhtarNNielsenMSvendsenLAndersenP.Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing.2018;113:686–93.10.1111/vox.1269930043984Search in Google Scholar
Sigle JP, Mihm B, Suna R, Bargetzi M. Extending shelf life of dithiothreitol-treated panel RBC s to 28 days. Vox Sang 2018;113:397–9.SigleJPMihmBSunaRBargetziM.Extending shelf life of dithiothreitol-treated panel RBC s to 28 days.2018;113:397–9.10.1111/vox.1264529512161Search in Google Scholar
Disbro WL. Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab. Immunohematology 2017;33:105–9.DisbroWL.Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab.2017;33:105–9.10.21307/immunohematology-2019-015Search in Google Scholar
Hugan SL, Cooling L, Larsson VM. An evaluation of storage time for dithiothreitol-treated reagent cells. Transfusion 2017; 57:2545–6.HuganSLCoolingLLarssonVM.An evaluation of storage time for dithiothreitol-treated reagent cells.2017;57:2545–6.10.1111/trf.1424428944543Search in Google Scholar
Scalea B. Phase III isatuximab trial meets primary endpoint of improving PFS in relapsed/refractory myeloma. Available at: https://www.targetedonc.com/news/phase-iii-isatuximab-trial-meets-primary-endpoint-of-improving-pfs-in-relapsedrefractory-myeloma. Accessed February 2020.ScaleaB.. Available at: https://www.targetedonc.com/news/phase-iii-isatuximab-trial-meets-primary-endpoint-of-improving-pfs-in-relapsedrefractory-myeloma. Accessed February 2020.Search in Google Scholar
Setia R, Dogra M, Sachdeva P, Handoo A, Choudhary D, Agarwal A. Daratumumab (anti-CD38) interference with serological testing: an emerging challenge for blood banks in developing countries. Glob J Transfus Med 2017;2:163–5.SetiaRDograMSachdevaPHandooAChoudharyDAgarwalA.Daratumumab (anti-CD38) interference with serological testing: an emerging challenge for blood banks in developing countries.2017;2:163–5.10.4103/GJTM.GJTM_42_17Search in Google Scholar
Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 2015;55:1555–62.OostendorpMLammerts van BuerenJJDoshiP,When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.2015;55:1555–62.10.1111/trf.1315025988285Search in Google Scholar
Lippi G. Systematic assessment of the hemolysis index: pros and cons. Adv Clin Chem 2015;71:157–70.LippiG.Systematic assessment of the hemolysis index: pros and cons.2015;71:157–70.10.1016/bs.acc.2015.05.00226411414Search in Google Scholar
Chari A, Arinsburg S, Jagannath S, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2018; 18:44–51.ChariAArinsburgSJagannathS,Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma.2018;18:44–51.10.1016/j.clml.2017.09.00229054515Search in Google Scholar
Hannon JL, Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma. Transfusion 2015;55:2770.HannonJLClarkeG.Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma.2015;55:2770.10.1111/trf.1326726559402Search in Google Scholar
Tiwari AK, Aggarwal G. Daratumumab affecting the pretransfusion testing: approach to finding compatible RBC unit. Glob J Transfus Med 2017;2:166–7.TiwariAKAggarwalG.Daratumumab affecting the pretransfusion testing: approach to finding compatible RBC unit.2017;2:166–7.10.4103/GJTM.GJTM_44_17Search in Google Scholar